Literature DB >> 289433

Prognostic factors affecting remission, remission duration, and survival in adult acute nonlymphocytic leukemia.

J Brandman, R M Bukowski, R Greenstreet, J S Hewlett, G C Hoffman.   

Abstract

The medical records of 94 consecutive patients with acute nonlymphocytic leukemia (ANLL) were reviewed to identify significant prognostic factors. The data were analyzed using 1) Cox's linear hazard and linear logistic models, 2) chi-square comparison of the groups living longer than 2 years and those living less than 2 years, and 3) the Gehan-Breslow test of equal survival curves. The only statistically significant finding was that the presence of promyelocytic cell type and complete remission correlated with increased survival (p less than .05), but this was negated by the small number of patients with this cell type. There was a suggestive association between higher initial hemoglobin and survival (p = .09). The Gehan-Breslow test revealed a possible difference in survival between those patients more than 51 years of age and those less than 51 (p = .10). Thus none of the commonly accepted prognostic factors in acute nonlymphocytic leukemia was definitely shown to be useful. The findings of this study support an aggressive approach toward all patients with this disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 289433     DOI: 10.1002/1097-0142(197909)44:3<1062::aid-cncr2820440339>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  [Changes of therapy results in acute leukemia under different treatment schedules with special reference to gnotobiotic measures].

Authors:  H Link; H M Frauer; K Wilms; H D Waller
Journal:  Klin Wochenschr       Date:  1983-04-01

2.  Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults.

Authors:  K Ota; S Kurita; K Yamada; T Masaoka; Y Uzuka; N Ogawa
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.